What is Alto Neuroscience's D&A?

Alto Neuroscience (ANRO) reported D&A of $184K in Q1 2026.

How has Alto Neuroscience's D&A changed year-over-year?

Alto Neuroscience's D&A increased by 7.6% year-over-year, from $171K to $184K.

What is the long-term trend for Alto Neuroscience's D&A?

Over 2 years (2023 to 2025), Alto Neuroscience's D&A has grown at a 25.6% compound annual growth rate (CAGR), from $398K to $628K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Alto Neuroscience ANRO D&A

D&A at other companies

Xenon PharmaceuticalsXENE

$587K-10.9%

Acadia PharmaceuticalsACAD

$271K+18.3%

Rapport Therapeutics, Inc.RAPP

$227K-7.0%

Praxis Precision Medicines, Inc.PRAX

$39K-17.0%

MeiraGTx Holdings plcMGTX

$3.01M-2.4%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$82K+3.8%

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$887.88M+1,358%

Enterprise value$644.49M-958%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's D&A?: Alto Neuroscience (ANRO) reported D&A of $184K in Q1 2026.
How has Alto Neuroscience's D&A changed year-over-year?: Alto Neuroscience's D&A increased by 7.6% year-over-year, from $171K to $184K.
What is the long-term trend for Alto Neuroscience's D&A?: Over 2 years (2023 to 2025), Alto Neuroscience's D&A has grown at a 25.6% compound annual growth rate (CAGR), from $398K to $628K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.